Partner
Anthony Tridico, Ph.D., former managing partner of Finnegan's London office and current member of the management committee, has worked in Europe for most of his career, gaining significant knowledge of the European Patent Convention (EPC) and the diversity of laws and practice among the European national systems. His knowledge of the various legal systems and how they differ from the U.S. allows Anthony to effectively counsel clients across life sciences industries with global interests in intellectual property.
Anthony has over 20 years of experience representing clients with a focus on patent office trials and appeals (PTAB and EPO), patent prosecution management, IP due diligence and litigation. His practice includes experience in a variety of technical areas including biologics, immunology and biotechnology, chemical and pharmaceutical sciences, polymers and adhesives, food sciences, medical devices, and diagnostics and instrumentation.
A significant portion of Anthony's current practice is devoted to post-grant proceedings, appeals and oral hearings at the Patent Trial and Appeal Board (PTAB) of the U.S. Patent and Trademark Office (USPTO), as well as European Patent Office (EPO) opposition and appeal procedures. Anthony, serving as lead counsel, has argued and won on behalf of both patent owners and petitioners in inter partes and ex partes proceedings before the PTAB. He has successfully represented numerous clients in inter partes reexaminations and ex parte reexaminations post-grant proceedings invaliding competitor patents and helping to clear the way for freedom to operate.
Anthony also focuses on international patent prosecution and portfolio management as well as strategic counseling including pre-litigation strategy, due diligence investigations, freedom to operate analysis and the specialized areas of patent term extensions and Orange Book listings. He works closely with clients to develop IP strategies with an eye towards litigation. He has also successfully represented clients in U.S. district court and multi-national patent litigations including protecting the rights of innovative pharmaceutical companies in Abbreviated New Drug Application (ANDA) litigations.
Anthony is a well-known authority on various intellectual property issues and is a frequent speaker at international programs and conferences and he has spoken before numerous Fortune 500 companies and multi-national organizations throughout the world. He served for over 10 years as adjunct professor at Georgetown University Law School teaching patent law and patent prosecution, and he is a lecturer on U.S. patent law at Queen Mary University of London.
Over the years, Anthony has been recognized by Intellectual Asset Management as a leading patent prosecutor in the United Kingdom and Europe in the IAM Patent 1000, and as a Global Leader as well as a top IP strategist by the IAM Strategy 300. Managing Intellectual Property named him an "IP Star" in the United Kingdom.
Anthony is currently lead counsel for several clients in the chemical and biotech industries in inter partes review (IPR) post-grant review (PGR) proceedings challenging the validity of competitor patents. He is also defending a client in an inter partes reexamination and appeal before the PTAB regarding its patent portfolio directed to G-CSF analogs. For another client, he is coordinating European opposition proceedings while providing strategic counseling of the U.S. patent portfolio for a European biotech company regarding a FDA-approved product. He provides strategic counseling, patent prosecution, and portfolio management of the global IP portfolio for Capsugel following the $2 billion spin off of the company from Pfizer.
1:09-cv-00286, 1:10-cv-00800, D. Del., Judges Farnan, Robinson, Thynge
12-1498, -1499, Fed. Cir., Judges Dyk, O'Malley, Wallach
Represented Dako in defending against patent infringement allegations involving diagnostic tests for Her2 gene. Successfully defended against a PI motion and later prevailed on summary judgment. On appeal, Federal Circuit affirmed noninfringement of one patent and remanded as to the second patent.
3:05-cv-03955, N.D. Cal., Judge Patel
07-1202, Fed. Cir., Judges Lourie, Mayer, Prost
Lead counsel successfully representing Grünenthal GmbH (patentee) before the PTAB against a challenge by Rosellini Scientific, LLC involving the FDA marketed products Nucynta® and Nucynta® ER, resulting in the PTAB denying institution of IPR.
IPR2016-00471, PTAB, Judges Hulse, Scheiner, Yang
Lead counsel in successful representation of Henkel Corporation before the PTAB against H.B. Fuller Co., resulting in all of the challenged claims being found unpatentable.
IPR2014-00606, PTAB, Judges Crumbley, Murphy, Praiss
IPR2018-00311, PTAB, Judges Heaney, Kokoski, Abraham
2:16-cv-02449, 2:16-cv-03743, 2:15-cv-05909, D.N.J., Judges McNulty, Clark
IPR2016-00286, -01582, PTAB, Judges Elluru, Green, Kalan
1:17-cv-00414, D. Del., Judges Goldberg, Thynge
IPR2017-01512, PTAB, Judges Ankenbrand, Fitzpatrick, Green
2:13-cv-04507, -06929, -07803; 2:14-cv-03941, -04617; 2:15-cv-06797, D.N.J., Judges Cecchi, Falk
1:12-cv-08060, S.D.N.Y., Judges Griesa, Daniels, Gorenstein
1:12-cv-00682, E.D. Va., Judges Trenga, Jones
Pronova Biopharma Norge AS v. Teva Pharmaceuticals USA, Inc.
Represented Pronova in Hatch-Waxman patent litigation concerning multiple ANDAs for generic versions of drug Lovaza®, resulting in judgment of patent infringement, validity, and enforceability in Pronova's favor.
1:09-cv-00286, 1:10-cv-00800, D. Del., Judges Farnan, Robinson, Thynge
12-1498, -1499, Fed. Cir., Judges Dyk, O'Malley, Wallach
Regents of the Univ. of California v. Dako
Represented Dako in defending against patent infringement allegations involving diagnostic tests for Her2 gene. Successfully defended against a PI motion and later prevailed on summary judgment. On appeal, Federal Circuit affirmed noninfringement of one patent and remanded as to the second patent.
3:05-cv-03955, N.D. Cal., Judge Patel
07-1202, Fed. Cir., Judges Lourie, Mayer, Prost
Rosellini Scientific, LLC, LLC v. Grunenthal GmbH
Lead counsel successfully representing Grünenthal GmbH (patentee) before the PTAB against a challenge by Rosellini Scientific, LLC involving the FDA marketed products Nucynta® and Nucynta® ER, resulting in the PTAB denying institution of IPR.
IPR2016-00471, PTAB, Judges Hulse, Scheiner, Yang
Lead counsel in successful representation of Henkel Corporation before the PTAB against H.B. Fuller Co., resulting in all of the challenged claims being found unpatentable.
IPR2014-00606, PTAB, Judges Crumbley, Murphy, Praiss
Siemens Healthcare Diagnostics Inc. v. Radiometer Medical ApS
IPR2018-00311, PTAB, Judges Heaney, Kokoski, Abraham
BTG Inc., Ltd v. Actavis Labs FL Inc.; Amneal Pharms LLC
2:16-cv-02449, 2:16-cv-03743, 2:15-cv-05909, D.N.J., Judges McNulty, Clark
IPR2016-00286, -01582, PTAB, Judges Elluru, Green, Kalan
Event
Inadmissible Extension: Pitfalls in European and U.S. Proceedings Inadmissible Extension: Pitfalls in European and U.S. Proceedings
April 25, 2023
Munich
Event
Synergistic and Surprisingly Effective: Inventive Step and Non-obviousness in Chemical and Life Sciences Cases Synergistic and Surprisingly Effective: Inventive Step and Non-obviousness in Chemical and Life Sciences Cases
January 20, 2022
Webinar
Event
When Novelty and Non-obviousness Aren’t Enough: Meeting the Requirements of Sufficiency, Enablement and Clarity in Chemical and Life Sciences Cases When Novelty and Non-obviousness Aren’t Enough: Meeting the Requirements of Sufficiency, Enablement and Clarity in Chemical and Life Sciences Cases
October 28, 2021
Webinar
“U.S.-headquartered Finnegan’s patent star across the Atlantic is Anthony Tridico: his instant recall of both European and U.S. case law and Ph.D. in physical chemistry give him the tools to deal with the most technically and legally challenging patent briefs.”
Intellectual Asset Management Patent 1000
“Life sciences doyen Anthony Tridico is managing partner of Finnegan’s London office; his knowledge of legal systems globally is invaluable on multi-jurisdictional patent prosecution briefs.”
Intellectual Asset Management Patent 1000
“He is fun, quick and sees legal issues, and can offer creative solutions.”
Intellectual Asset Management Patent 1000
“Anthony Tridico is managing partner of Finnegan Europe’s London office; his knowledge of Stateside systems is a boon for westward-looking rights holders.”
Intellectual Asset Management Patent 1000
“Anthony Tridico of Finnegan, Henderson, Farabow, Garrett & Dunner is ‘always fully 100% committed. He is really engaged, committed, bright and an expert on the regulatory patent boundary. He is brilliant on litigation strategising too—he has a good understanding of both U.S. and European IP legislation.’”
Intellectual Asset Management Patent 1000
“Finnegan’s Anthony Tridico is a diligent drafter whose extremely personal and hands-on service has won him fans across the board.”
Intellectual Asset Management Patent 1000
“Anthony Tridico of Finnegan is a leading patent prosecutor and manager of complex portfolios—as head of the London office, he is a vital link between the firm’s European and U.S. offerings.”
Intellectual Asset Management Patent 1000
“U.S.-headquartered Finnegan’s patent star across the Atlantic is Anthony Tridico: his instant recall of both European and U.S. case law and Ph.D. in physical chemistry give him the tools to deal with the most technically and legally challenging patent briefs.”
Intellectual Asset Management Patent 1000
“Life sciences doyen Anthony Tridico is managing partner of Finnegan’s London office; his knowledge of legal systems globally is invaluable on multi-jurisdictional patent prosecution briefs.”
Intellectual Asset Management Patent 1000
“He is fun, quick and sees legal issues, and can offer creative solutions.”
Intellectual Asset Management Patent 1000
“Anthony Tridico is managing partner of Finnegan Europe’s London office; his knowledge of Stateside systems is a boon for westward-looking rights holders.”
Intellectual Asset Management Patent 1000
“Anthony Tridico of Finnegan, Henderson, Farabow, Garrett & Dunner is ‘always fully 100% committed. He is really engaged, committed, bright and an expert on the regulatory patent boundary. He is brilliant on litigation strategising too—he has a good understanding of both U.S. and European IP legislation.’”
Intellectual Asset Management Patent 1000
“Finnegan’s Anthony Tridico is a diligent drafter whose extremely personal and hands-on service has won him fans across the board.”
Intellectual Asset Management Patent 1000
“Anthony Tridico of Finnegan is a leading patent prosecutor and manager of complex portfolios—as head of the London office, he is a vital link between the firm’s European and U.S. offerings.”
Intellectual Asset Management Patent 1000
Award/Ranking
Eleven Finnegan Attorneys Named to the 2024 IAM Strategy 300 List
Eleven Finnegan Attorneys Named to the 2024 IAM Strategy 300 List
August 14, 2024
IAMAward/Ranking
Finnegan Ranks at the Top of the Managing Intellectual Property IP Stars Rankings Finnegan Ranks at the Top of the Managing Intellectual Property IP Stars Rankings
June 28, 2024
Managing Intellectual PropertyAward/Ranking
10 Finnegan Attorneys Named to the 2023 IAM Strategy 300 List 10 Finnegan Attorneys Named to the 2023 IAM Strategy 300 List
October 5, 2023
Intellectual Asset ManagementPress Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyPress Release
45 Finnegan Attorneys Recommended by Intellectual Asset Management; Firm Continues to Be Top Ranked 45 Finnegan Attorneys Recommended by Intellectual Asset Management; Firm Continues to Be Top Ranked
July 8, 2022
Intellectual Asset ManagementAnnouncement
More than 30 Finnegan Attorneys Named to IP Stars List by Managing IP More than 30 Finnegan Attorneys Named to IP Stars List by Managing IP
June 1, 2022
Managing Intellectual PropertyDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.